Inogen (NASDAQ:INGN) had its price target boosted by Piper Jaffray Companies from $245.00 to $290.00 in a research report report published on Wednesday, The Fly reports. They currently have an overweight rating on the medical technology company’s stock.
A number of other research analysts also recently issued reports on INGN. Zacks Investment Research upgraded shares of Inogen from a hold rating to a buy rating and set a $276.00 target price for the company in a research report on Tuesday, August 28th. Needham & Company LLC restated a buy rating on shares of Inogen in a research report on Wednesday, June 13th. BidaskClub downgraded shares of Inogen from a strong-buy rating to a buy rating in a research report on Tuesday, July 31st. KeyCorp assumed coverage on shares of Inogen in a research report on Wednesday, June 6th. They set an equal weight rating for the company. Finally, Stifel Nicolaus set a $258.00 target price on shares of Inogen and gave the company a buy rating in a research report on Tuesday, August 21st. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Inogen currently has an average rating of Buy and an average price target of $245.00.
NASDAQ INGN opened at $282.92 on Wednesday. The firm has a market cap of $5.87 billion, a P/E ratio of 215.97, a price-to-earnings-growth ratio of 5.44 and a beta of 1.24. Inogen has a 1 year low of $91.80 and a 1 year high of $287.79.
In other Inogen news, Director Ray Benjamin M. Anderson sold 1,000 shares of the company’s stock in a transaction dated Monday, July 2nd. The shares were sold at an average price of $184.88, for a total value of $184,880.00. Following the completion of the transaction, the director now owns 1,989 shares in the company, valued at $367,726.32. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Byron Myers sold 24,953 shares of the company’s stock in a transaction dated Thursday, August 9th. The stock was sold at an average price of $227.13, for a total transaction of $5,667,574.89. Following the completion of the transaction, the executive vice president now owns 42,329 shares of the company’s stock, valued at approximately $9,614,185.77. The disclosure for this sale can be found here. In the last quarter, insiders sold 103,710 shares of company stock valued at $21,855,102. Insiders own 5.29% of the company’s stock.
Several institutional investors have recently modified their holdings of INGN. WINTON GROUP Ltd raised its position in shares of Inogen by 382.8% during the 2nd quarter. WINTON GROUP Ltd now owns 67,012 shares of the medical technology company’s stock worth $12,486,000 after purchasing an additional 53,133 shares during the last quarter. California Public Employees Retirement System raised its position in shares of Inogen by 4.6% during the 2nd quarter. California Public Employees Retirement System now owns 31,149 shares of the medical technology company’s stock worth $5,804,000 after purchasing an additional 1,376 shares during the last quarter. AE Wealth Management LLC acquired a new position in shares of Inogen during the 2nd quarter worth about $877,000. Zacks Investment Management raised its position in shares of Inogen by 1.6% during the 2nd quarter. Zacks Investment Management now owns 17,033 shares of the medical technology company’s stock worth $3,174,000 after purchasing an additional 261 shares during the last quarter. Finally, Lido Advisors LLC acquired a new position in shares of Inogen during the 2nd quarter worth about $302,000. Institutional investors and hedge funds own 96.49% of the company’s stock.
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Featured Story: Hedge Funds Explained
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.